Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II study

Studies in experimental human lung cancer models have suggested that interferon may enhance significantly the response to some cytotoxic drugs. We have performed a phase II study of cisplatin (100 mg/m2 q.21 or 28 days) and alpha-2 interferon (3 or 5 MU three times weekly) in 68 patients with advanc...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1990-09, Vol.1 (5), p.351-353
Main Authors: Bowman, A., Fergussion, R.J., Allan, S.G., Stewart, M.E., Gregor, A., Combleet, M.A., Greening, A.P., Crompton, G.K., Leonard, R.C.F., Smyth, J.F.
Format: Article
Language:English
Subjects:
alpha-interferon
cisplatin
non-small cell cancer
potetiation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies in experimental human lung cancer models have suggested that interferon may enhance significantly the response to some cytotoxic drugs. We have performed a phase II study of cisplatin (100 mg/m2 q.21 or 28 days) and alpha-2 interferon (3 or 5 MU three times weekly) in 68 patients with advanced non-small cell lung cancer and good performance status. As toxicity was acceptable, the dose of interferon and schedule of cisplatin were increased at the midpoint of the study. 46% (11/24) of patients with squamous carcinoma responded and an overall partial response rate of 30% was attained in 60 evaluable patients. There was no potentiation of haematological, renal or neurological toxicity but nausea and vomiting were severe. These results suggest that the combination has activity in this usually refractory disease.
ISSN:0923-7534
1569-8041
DOI:10.1093/oxfordjournals.annonc.a057773